Copyright
©The Author(s) 2021.
World J Gastrointest Pharmacol Ther. Nov 5, 2021; 12(6): 103-112
Published online Nov 5, 2021. doi: 10.4292/wjgpt.v12.i6.103
Published online Nov 5, 2021. doi: 10.4292/wjgpt.v12.i6.103
Table 1 Basic demographics of patients and indications for colon capsule endoscopy, n (%)
| Total | With castor oil | Without castor oil | P value | |
| 186 | 62 | 124 | ||
| Age | 0.2365 | |||
| Mean | 60.0 | 62.0 | 59.0 | |
| Range | 18-97 | 22-97 | 18-86 | |
| Gender | 0.8357 | |||
| Male | 82 (44%) | 28 (45.2) | 54 (43.5) | |
| Female | 104 (56%) | 34 (54.8) | 70 (56.5) | |
| Indications | ||||
| Polyp surveillance | 96 | 30/62 (48.4) | 66/124 (53.2) | 0.5362 |
| Lower gastrointestinal symptoms | 42 | 10/62 (16.1) | 32/124 (25.8) | 0.1382 |
| Incomplete colonoscopy | 28 | 11/62 (17.7) | 17/124 (13.7) | 0.4712 |
| Anaemia | 18 | 10/62 (16.1) | 8/124 (6.5) | 0.0355 |
| IBD surveillance | 2 | 1/62 (1.6) | 1/124 (0.8) | 0.6174 |
Table 2 Effects of castor oil on colon capsule endoscopy performance, n (%)
| Variables | Overall | With castor oil | Without castor oil | P value |
| Capsule completion | 144/186 (77) | 54/62 (87) | 90/124 (73) | 0.0128 |
| Image quality(adequate/diagnostic) | 170/186 (91) | 56/62 (90) | 114/124 (92) | 0.3558 |
| Colonic transit time (hr) | ||||
| Mean: | 3.5 | 3.2 | 3.8 | 0.1779 |
| 95%CI: -2.90 to 0.54 | ||||
| Range: | 0.25-13 | 0.25-13 | 0.5-13 | |
| CCE positivity | 109/186 (59) | 52/62 (84) | 57/124 (46) | < 0.0001 |
| CI: 2.85 to 13.11 | ||||
| OR 6.1 | ||||
| Polyp detection rate | 106/186 (57) | 51/62 (82) | 55/124 (44) | < 0.0001 |
| CI: 2.77 to 12.21 | ||||
| OR 5.8 |
Table 3 Colon capsule endoscopy completion vs non-completion, n (%)
| Variable | Total | With castor oil | Without castor oil | P value |
| Overall capsule completion | 144/186 (77) | 54/62 (87) | 90/124 (73) | 0.0128 |
| Age: | ||||
| ≤ 60 | 67/78 (86) | 24/26 (92) | 43/52 (83) | 0.1250 |
| > 60 | 77/108 (71) | 30/36 (83) | 47/72 (65) | 0.0253 |
| Gender: | ||||
| Male | 68/82 (83) | 25/28 (89) | 43/54 (80) | 0.1352 |
| Female | 76/104 (73) | 29/34 (85) | 47/70 (67) | 0.0251 |
| Indication: | ||||
| Polyp surveillance | 75/96 (78) | 28/30 (93) | 47/66 (71) | 0.0075 |
| Lower gastrointestinal symptoms | 36/42 (86) | 10/10 (100) | 26/32 (81) | 0.0450 |
| Incomplete colonoscopy | 19/28 (68) | 7/11 (63) | 12/17 (7) | 0.3502 |
| Anaemia | 12/18 (67) | 8/10 (80) | 4/8 (50) | 0.0899 |
| IBD surveillance | 2/2 (100) | 1/1 (100) | 1/1 (100) | 1.0 |
- Citation: Semenov S, Ismail MS, O'Hara F, Sihag S, Ryan B, O'Connor A, O'Donnell S, McNamara D. Addition of castor oil as a booster in colon capsule regimens significantly improves completion rates and polyp detection. World J Gastrointest Pharmacol Ther 2021; 12(6): 103-112
- URL: https://www.wjgnet.com/2150-5349/full/v12/i6/103.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v12.i6.103